Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial

Mahamadou A Thera, Ogobara K Doumbo, Drissa Coulibaly, Matthew B Laurens, Abdoulaye K Kone, Ando B Guindo, Karim Traore, Mady Sissoko, Dapa A Diallo, Issa Diarra, Bourema Kouriba, Modibo Daou, Amagana Dolo, Mounirou Baby, Mahamadou S Sissoko, Issaka Sagara, Amadou Niangaly, Idrissa Traore, Ally Olotu, Olivier Godeaux, Amanda Leach, Marie-Claude Dubois, W Ripley Ballou, Joe Cohen, Darby Thompson, Tina Dube, Lorraine Soisson, Carter L Diggs, Shannon L Takala, Kirsten E Lyke, Brent House, David E Lanar, Sheetij Dutta, D Gray Heppner, Christopher V Plowe, Mahamadou A Thera, Ogobara K Doumbo, Drissa Coulibaly, Matthew B Laurens, Abdoulaye K Kone, Ando B Guindo, Karim Traore, Mady Sissoko, Dapa A Diallo, Issa Diarra, Bourema Kouriba, Modibo Daou, Amagana Dolo, Mounirou Baby, Mahamadou S Sissoko, Issaka Sagara, Amadou Niangaly, Idrissa Traore, Ally Olotu, Olivier Godeaux, Amanda Leach, Marie-Claude Dubois, W Ripley Ballou, Joe Cohen, Darby Thompson, Tina Dube, Lorraine Soisson, Carter L Diggs, Shannon L Takala, Kirsten E Lyke, Brent House, David E Lanar, Sheetij Dutta, D Gray Heppner, Christopher V Plowe

Abstract

Background: The objective was to evaluate the safety and immunogenicity of the AMA1-based malaria vaccine FMP2.1/AS02(A) in children exposed to seasonal falciparum malaria.

Methodology/principal findings: A Phase 1 double blind randomized controlled dose escalation trial was conducted in Bandiagara, Mali, West Africa, a rural town with intense seasonal transmission of Plasmodium falciparum malaria. The malaria vaccine FMP2.1/AS02(A) is a recombinant protein (FMP2.1) based on apical membrane antigen 1 (AMA1) from the 3D7 clone of P. falciparum, formulated in the Adjuvant System AS02(A). The comparator vaccine was a cell-culture rabies virus vaccine (RabAvert). One hundred healthy Malian children aged 1-6 years were recruited into 3 cohorts and randomized to receive either 10 microg FMP2.1 in 0.1 mL AS02(A), or 25 microg FMP2.1 in 0.25 mL AS02(A), or 50 microg FMP2.1 50 microg in 0.5 mL AS02(A), or rabies vaccine. Three doses of vaccine were given at 0, 1 and 2 months, and children were followed for 1 year. Solicited symptoms were assessed for 7 days and unsolicited symptoms for 30 days after each vaccination. Serious adverse events were assessed throughout the study. Transient local pain and swelling were common and more frequent in all malaria vaccine dosage groups than in the comparator group, but were acceptable to parents of participants. Levels of anti-AMA1 antibodies measured by ELISA increased significantly (at least 100-fold compared to baseline) in all 3 malaria vaccine groups, and remained high during the year of follow up.

Conclusion/significance: The FMP2.1/AS02(A) vaccine had a good safety profile, was well-tolerated, and induced high and sustained antibody levels in malaria-exposed children. This malaria vaccine is being evaluated in a Phase 2 efficacy trial in children at this site.

Trial registration: ClinicalTrials.gov NCT00358332 [NCT00358332].

Conflict of interest statement

Competing Interests: SD and DEL hold patents for the FMP2.1 vaccine antigen. OG, AL, WRB, MCD and JC are or were employees of GlaxoSmithKline Biologicals, the manufacturer of the proprietary Adjuvant System AS02A, and hold shares in GlaxoSmithKline. None of the other authors have declared conflict of interest.

Figures

Figure 1. Trial profile.
Figure 1. Trial profile.
Figure 2. Grade 3 injection site swelling…
Figure 2. Grade 3 injection site swelling 1–2 days following immunization with the malaria vaccine.
Injection site swelling was considered grade 3 if it exceeded 20 mm in its widest dimension. Grade 3 swelling was typically unnoticed by participants and parents and came to attention only during physical examinations. It was transient, lasting 1–3 days, and not associated with functional impairment. Shown here is grade 3 injection site swelling of the left shoulder of a study participant.
Figure 3. Anti-AMA1 antibody levels.
Figure 3. Anti-AMA1 antibody levels.
Geometric mean of antibodies (µg/mL) to homologous recombinant AMA1 for FMP2.1/AS02A 50 µg dose, FMP2.1/AS02A 25 µg dose, FMP2.1/AS02A 10 µg dose and rabies vaccine recipients. Times of each of 3 immunizations are indicated by arrows. Error bars represent 95 percent confidence intervals.

References

    1. Kocken CH, van der Wel AM, Dubbeld MA, Narum DL, van de Rijke FM, et al. Precise timing of expression of a Plasmodium falciparum-derived transgene in Plasmodium berghei is a critical determinant of subsequent subcellular localization. J Biol Chem. 1998;273:15119–15124.
    1. Deans JA, Alderson T, Thomas AW, Mitchell GH, Lennox ES, et al. Rat monoclonal antibodies which inhibit the in vitro multiplication of Plasmodium knowlesi. Clin Exp Immunol. 1982;49:297–309.
    1. Thomas AW, Deans JA, Mitchell GH, Alderson T, Cohen S. The Fab fragments of monoclonal IgG to a merozoite surface antigen inhibit Plasmodium knowlesi invasion of erythrocytes. Mol Biochem Parasitol. 1984;13:187–199.
    1. Hodder AN, Crewther PE, Anders RF. Specificity of the protective antibody response to apical membrane antigen 1. Infect Immun. 2001;69:3286–3294.
    1. Dutta S, Haynes JD, Moch JK, Barbosa A, Lanar DE. Invasion-inhibitory antibodies inhibit proteolytic processing of apical membrane antigen 1 of Plasmodium falciparum merozoites. Proc Natl Acad Sci U S A. 2003;100:12295–12300.
    1. Thomas AW, Trape JF, Rogier C, Goncalves A, Rosario VE, et al. High prevalence of natural antibodies against Plasmodium falciparum 83-kilodalton apical membrane antigen (PF83/AMA-1) as detected by capture-enzyme-linked immunosorbent assay using full-length baculovirus recombinant PF83/AMA-1. Am J Trop Med Hyg. 1994;51:730–740.
    1. Udhayakumar V, Kariuki S, Kolczack M, Girma M, Roberts JM, et al. Longitudinal study of natural immune responses to the Plasmodium falciparum apical membrane antigen (AMA-1) in a holoendemic region of malaria in western Kenya: Asembo Bay Cohort Project VIII. Am J Trop Med Hyg. 2001;65:100–107.
    1. Heppner DG, Jr, Kester KE, Ockenhouse CF, Tornieporth N, Ofori O, et al. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine. 2005;23:2243–2250.
    1. Takala SL, Coulibaly D, Thera MA, Batchelor AH, Cummings MP, et al. Extreme polymorphism in a vaccine antigen and risk of clinical malaria: Implications for vaccine development. Sci Transl Med. 2009;1:2ra5.
    1. Healer J, Murphy V, Hodder AN, Masciantonio R, Gemmill AW, et al. Allelic polymorphisms in apical membrane antigen-1 are responsible for evasion of antibody-mediated inhibition in Plasmodium falciparum. Mol Microbiol. 2004;52:159–168.
    1. Kennedy MC, Wang J, Zhang Y, Miles AP, Chitsaz F, et al. In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. Infect Immun. 2002;70:6948–6960.
    1. Kocken CH, Withers-Martinez C, Dubbeld MA, van der WA, Hackett F, et al. High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion. Infect Immun. 2002;70:4471–4476.
    1. Takala SL, Plowe CV. Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming ‘vaccine resistant malaria’. Parasite Immunol. 2009;31:560–573.
    1. Dutta S, Lee SY, Batchelor AH, Lanar DE. Structural basis of antigenic escape of a malaria vaccine candidate. Proc Natl Acad Sci U S A. 2007;104:12488–12493.
    1. Duan J, Mu J, Thera MA, Joy D, Kosakovsky Pond SL, et al. Population structure of the genes encoding the polymorphic Plasmodium falciparum apical membrane antigen 1: implications for vaccine design. Proc Natl Acad Sci U S A. 2008;105:7857–7862.
    1. Polhemus ME, Magill AJ, Cummings JF, Kester KE, Ockenhouse CF, et al. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine. 2007;25:4203–4212.
    1. Thera MA, Doumbo OK, Coulibaly D, Diallo DA, Kone AK, et al. Safety and Immunogenicity of an AMA-1 Malaria Vaccine in Malian Adults: Results of a Phase 1 Randomized Controlled Trial. PLoS ONE. 2008;3:e1465.
    1. Malkin EM, Diemert DJ, McArthur JH, Perreault JR, Miles AP, et al. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria. Infect Immun. 2005;73:3677–3685.
    1. Dicko A, Sagara I, Ellis RD, Miura K, Guindo O, et al. Phase 1 study of a combination AMA1 blood stage malaria vaccine in Malian children. PLoS ONE. 2008;3:e1563.
    1. Sagara I, Dicko A, Ellis RD, Fay MP, Diawara SI, et al. A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali. Vaccine. 2009;27:3090–3098.
    1. Dutta S, Lalitha PV, Ware LA, Barbosa A, Moch JK, et al. Purification, characterization, and immunogenicity of the refolded ectodomain of the Plasmodium falciparum apical membrane antigen 1 expressed in Escherichia coli. Infect Immun. 2002;70:3101–3110.
    1. Lyke KE, Daou M, Diarra I, Kone A, Kouriba B, et al. Cell-mediated immunity elicited by the blood stage malaria vaccine apical membrane antigen 1 in Malian adults: results of a Phase I randomized trial. Vaccine. 2009;27:2171–2176.
    1. Lyke KE, Dicko A, Kone A, Coulibaly D, Guindo A, et al. Incidence of severe Plasmodium falciparum malaria as a primary endpoint for vaccine efficacy trials in Bandiagara, Mali. Vaccine. 2004;22:3169–3174.
    1. Coulibaly D, Diallo DA, Thera MA, Dicko A, Guindo AB, K, et al. Impact of preseason treatment on incidence of falciparum malaria and parasite density at a site for testing malaria vaccines in Bandiagara, Mali. Am J Trop Med Hyg. 2002;67:604–610.
    1. Diallo DA, Doumbo OK, Plowe CV, Wellems TE, Emanuel EJ, Hurst SA. Community permission for medical research in developing countries. Clin Infect Dis. 2005;41:255–259.
    1. Wu JY, Gardner BH, Murphy CI, Seals JR, Kensil CR, et al. Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine. J Immunol. 1992;148:1519–1525.
    1. Soltysik S, Bedore DA, Kensil CR. Adjuvant activity of QS-21 isomers. Ann N Y Acad Sci. 1993;690:392–395.
    1. Lugada ES, Mermin J, Kaharuza F, Ulvestad E, Were W, et al. Population-based hematologic and immunologic reference values for a healthy Ugandan population. Clin Diagn Lab Immunol. 2004;11:29–34.
    1. Thera MA, Doumbo OK, Coulibaly D, Diallo DA, Sagara I, et al. Safety and Allele-Specific Immunogenicity of a Malaria Vaccine in Malian Adults: Results of a Phase I Randomized Trial. PLoS Clin Trials. 2006;1:e34.
    1. Withers MR, McKinney D, Ogutu BR, Waitumbi JN, Milman JB, et al. Safety and Reactogenicity of an MSP-1 Malaria Vaccine Candidate: A Randomized Phase Ib Dose-Escalation Trial in Kenyan Children. PLoS Clin Trials. 2006;1:e32.
    1. Dutta S, Sullivan JS, Grady KK, Haynes JD, Komisar J, et al. High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model. PLoS ONE. 2009;4:e8138.
    1. Spring MD, Cummings JF, Ockenhouse CF, Dutta S, Reidler R, et al. Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. PLoS ONE. 2009;4:e5254.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe